INVO Fertility, Inc (NASDAQ:IVF) Stock Short Interest Declines 71.4%

INVO Fertility, Inc (NASDAQ:IVF) was the recipient of a significant decrease in short interest during the month of October. As of October 30th, there was short interest totaling 7,572 shares, a decrease of 71.4% from the October 15th total of 26,478 shares. Based on an average daily trading volume, of 31,162 shares, the short-interest ratio is currently 0.2 days. Approximately 1.2% of the company’s stock are short sold.

INVO Fertility Stock Down 3.0%

NASDAQ IVF traded down $0.08 during trading on Friday, hitting $2.60. 26,254 shares of the company traded hands, compared to its average volume of 431,634. INVO Fertility has a 12 month low of $1.59 and a 12 month high of $91.60. The business has a fifty day simple moving average of $10.69 and a 200 day simple moving average of $32.25. The company has a current ratio of 0.71, a quick ratio of 0.67 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.64 million, a P/E ratio of -0.02 and a beta of 2.42.

INVO Fertility (NASDAQ:IVF) last issued its quarterly earnings data on Friday, August 14th. The company reported $5.60 EPS for the quarter. The business had revenue of $2.18 million for the quarter. INVO Fertility had a negative return on equity of 85.54% and a negative net margin of 116.29%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on IVF. Wall Street Zen upgraded shares of INVO Fertility to a “hold” rating in a research note on Saturday, August 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of INVO Fertility in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to MarketBeat, INVO Fertility has an average rating of “Moderate Buy” and an average target price of $320.00.

INVO Fertility Company Profile

INVO Fertility, Inc. is a commercial-stage fertility company focused on expanding access to assisted reproductive technology. The company develops and commercializes fertility products and services designed to provide alternatives to conventional in vitro fertilization (IVF) treatment. Its principal product is INVOcell, a medical device used in the INVO Procedure. The system allows early-stage embryo incubation to take place inside the patient’s body rather than in a conventional laboratory incubator, while still involving the retrieval of eggs, fertilization, and subsequent embryo transfer under the supervision of fertility professionals.